The first and only body-identical HRT for post-menopausal oestrogen deficiency, Bijuve, has been passed by the SMC as suitable for use by Scotland’s National Health Service, after being adv
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
